Adjusted hazard ratio (HR) for risk of major adverse cardiovascular events (MACE) in patients prescribed, compared with those not prescribed, ACE inhibitor, stratified by NT-proBNP concentration
| Hazard ratio (95% CI) | ||||
| Univariable | p Value | Multivariable | p Value | |
| NT-proBNP quartile* | 2.417 (2.099 to 2.784) | <0.001 | 1.843 (1.401 to 2.424) | <0.001 |
| Top quartile NT-proBNP | 0.613 (0.459 to 0.818) | 0.001 | 0.597 (0.439 to 0.813) | 0.001 |
| Quartiles 1-3 NT-proBNP | 1.174 (0.898 to 1.535) | 0.241 | 1.114 (0.845 to 1.468) | 0.443 |
| Quartile 1 | 1.496 (0.870 to 2.572) | 0.146 | 1.231 (0.687 to 2.203) | 0.485 |
| Quartile 2 | 1.414 (0.846 to 2.364) | 0.187 | 1.341 (0.796 to 2.257) | 0.270 |
| Quartile 3 | 0.736 (0.500 to 1.082) | 0.119 | 0.938 (0.624 to 1.410) | 0.758 |
↵* NT-proBNP quartile considered as continuous variable.
HR was first calculated for NT-proBNP considered as a continuous variable. After demonstration of an interaction between NT-proBNP quartile and prescription of ACE inhibitor, HR for MACE in those prescribed an ACE inhibitor was calculated for quartile 4 of NT-proBNP, for quartiles 1–3, and for each quartile of NT-proBNP.